NLS Pharmaceutics AG: NLS Pharmaceutics To Host Virtual Key Opinion Leader Event on September 30, 2022 After Release of Quilience Top-Line Phase 2a Narcolepsy Results

ZURICH, SWITZERLAND / ACCESSWIRE / September 19, 2022 / NLS Pharmaceutics Ltd. (Nasdaq:NLSP), (Nasdaq:NLSPW) ("NLS" or the "Company"), a Swiss clinical-stage biopharmaceutical company focused on the discovery

Related Keywords

Switzerland ,Zurich ,Züsz ,Danville ,Ohio ,United States ,Cincinnati ,Swiss ,Alex Zwyer ,Bruce Corser ,Anne Marie Morse ,George Apostol ,Cindy Rizzo ,Pascal Nigen ,Novant Health ,Geisinger Medical Center ,Nasdaq ,Pharmaceutics Ltd ,Exchange Commission ,Alpha Bronze ,Management Institute ,European Medicines Agency ,Virtual Key Opinion Leader ,Chief Medical Officer ,Global Head ,Medical Director ,Sleep Management Institute ,Sleep Medicine ,Marie Morse ,Pediatric Neurology ,Advanced Respiratory ,Epworth Sleepiness Scale ,Orphan Disease Designation ,Mazindol Controlled Release ,Orphan Drug Designations ,Pharmaceutics ,Most ,Irtual ,Opinion ,Leader ,Event ,September ,022 ,After ,Release ,Uilience ,Line ,Hase ,Narcolepsy ,Results ,